Table 1.
Name | Antibody isotype | Recognizes | Commercially available | Positive control | Negative control | Reference |
---|---|---|---|---|---|---|
CTD110.6 | IgM | βGlcNAc | Covance, Pierce, Millipore SIGMA, Cell Signaling, Santa Cruz Biotechnology | BSA-AP-GlcNAc | BSA-APa or ovalbumin | (Comer et al., 2001) |
RL2 | IgG | O-GlcNAc | Abcam, Affinity Bioreagents, Santa Cruz Biotechnology | BSA-AP-GlcNAc | BSA-AP or ovalbumin | (Snow et al., 1987) |
MY95 | IgG | O-GlcNAc | No | BSA-AP-GlcNAc | BSA-AP or ovalbumin | (Matsuoka et al., 2002) |
18B10.C7(3) | IgG | O-GlcNAc | Millipore | BSA-AP-GlcNAc | BSA-AP or ovalbumin | (Teo et al., 2010) |
9D1.E4(10) | IgG | βGlcNAc | Millipore | BSA-AP-GlcNAc | BSA-AP or ovalbumin | (Teo et al., 2010) |
1F5.D6(14) | IgG | O-GlcNAc | Millipore | BSA-AP-GlcNAc | BSA-AP or ovalbumin | (Teo et al., 2010) |
HGAC 85 | IgG | βGlcNAc | Novus Biologicals, Abcam, Pierce, Enzo life sciences, Affinity Bioreagents | BSA-AP-GlcNAc | BSA-AP or BSA | (Turner et al., 1990) |
HGAC 49 | IgM | βGlcNAc | No | BSA-AP-GlcNAc | BSA-AP or BSA | (Turner et al., 1990) |
HGAC 39 | IgG | βGlcNAc | No | BSA-AP-GlcNAc | BSA-AP or BSA | (Turner et al., 1990) |
Multi-mAbb | IgG | O-GlcNAc | Cell Signaling Technology | BSA | N/A |
BSA-AP, BSA-aminophenol.
This antibody was raised against glycoproteins. Modulating O-GlcNAc levels is an appropriate control.